

**MEDICAL
INTELLIGENCE
UNIT**

Peptide Nucleic Acids,
Morpholinos and Related
Antisense Biomolecules

Christopher G. Janson, M.D.

Departments of Neurosurgery, Neurology and Molecular Genetics
Cell and Gene Therapy Center
UMDNJ-Robert Wood Johnson Medical School
Camden, New Jersey, U.S.A.

Matthew J. During, M.D., Sc.D.

Department of Molecular Medicine and Pathology
University of Auckland
Auckland, New Zealand

LANDES BIOSCIENCE / EUREKAH.COM
GEORGETOWN, TEXAS
U.S.A.

KLUWER ACADEMIC / PLENUM PUBLISHERS
NEW YORK, NEW YORK
U.S.A.

PEPTIDE NUCLEIC ACIDS, MORPHOLINOS AND RELATED ANTISENSE BIOMOLECULES

Medical Intelligence Unit

Landes Bioscience / Eureka.com
Kluwer Academic / Plenum Publishers

Copyright ©2006 Eureka.com and Kluwer Academic / Plenum Publishers

All rights reserved.

No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system; for exclusive use by the Purchaser of the work.

Printed in the U.S.A.

Kluwer Academic / Plenum Publishers, 233 Spring Street, New York, New York, U.S.A. 10013
<http://www.wkap.nl/>

Please address all inquiries to the Publishers:

Landes Bioscience / Eureka.com, 810 South Church Street, Georgetown, Texas, U.S.A. 78626

Phone: 512/ 863 7762; FAX: 512/ 863 0081

<http://www.eureka.com>

<http://www.landesbioscience.com>

Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules, edited by Christopher G. Janson and Matthew J. During, Landes / Kluwer dual imprint / Landes series: Medical Intelligence Unit

ISBN: 0-306-48230-4

While the authors, editors and publisher believe that drug selection and dosage and the specifications and usage of equipment and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they make no warranty, expressed or implied, with respect to material described in this book. In view of the ongoing research, equipment development, changes in governmental regulations and the rapid accumulation of information relating to the biomedical sciences, the reader is urged to carefully review and evaluate the information provided herein.

Library of Congress Cataloging-in-Publication Data

Peptide nucleic acids, morpholinos, and related antisense biomolecules

/ [edited by] Christopher G. Janson, Matthew J. During.

p. ; cm. -- (Medical intelligence unit)

ISBN 0-306-48230-4

1. Antisense nucleic acids. 2. Antisense peptides. I. Janson, Christopher G. II. During, Matthew J. III. Series: Medical intelligence unit (Unnumbered : 2003)

[DNLM: 1. Peptide Nucleic Acids. 2. Antisense Elements (Genetics)

QU 58 P42394 2006]

QP624.5.A57P47 2006

612'.015756--dc22

2005016425

This volume is dedicated to Dr. Linda Bartoshuk, who facilitated its planning by assisting one of the editors (Dr. Janson) during his leave from Yale University; and to Dr. Stanley Miller, who first proposed the role of PNA in prebiotic chemical evolution and the ancient history of life on Earth, thereby raising the question if the recent discovery of PNA was in fact a fortuitous rediscovery of our common pre-DNA, pre-RNA origins.

CONTENTS

Preface	xvii
---------------	------

Part I

Research Applications

1. The Many Faces of PNA	3
<i>Peter E. Nielsen</i>	
Introduction to PNA	3
PNA Chemistry	3
Cellular Uptake of PNA	4
Antisense Applications	5
Antigene Properties	5
Antimicrobial PNAs	9
Genetic Information Carrier	11
PNA in Diagnostics	12
Prospects	13
2. Modulation of Nucleic Acid Information Processing by PNAs: Potential Use in Anti-Viral Therapeutics	18
<i>Lionel Bastide, Bernard Lebleu and Ian Robbins</i>	
PNAs as Gene-Modulator Agents	21
Virus Specific Nucleic Acid Processing	25
PNA-Tuning	26
3. Targeted Gene Delivery: The Role of Peptide Nucleic Acid	30
<i>Kenneth W. Liang, Feng Liu and Leaf Huang</i>	
Targeted Gene Delivery through Polycation/DNA Complex	31
Targeted Delivery of Naked DNA	33
4. Imaging Gene Expression in the Brain with Peptide Nucleic Acid (PNA) Antisense Radiopharmaceuticals and Drug Targeting Technology	38
<i>Ruben J. Boado and William M. Pardridge</i>	
Mechanism of Action of Antisense Drugs	40
Medical Diagnostic and Therapeutic Applications	41
Functional Genomics	45
Overview of Antisense Molecules and Effective Delivery	45
Brain Drug Targeting Systems	47
Physiological Brain Efflux of IgG	52
Imaging of Brain Gene Expression	52

5. Receptor-Specific Targeting with Complementary Peptide Nucleic Acids Conjugated to Peptide Analogs and Radionuclides	61
<i>Eric Wickstrom, Mathew L. Thakur and Edward R. Sauter</i>	
Synthesis of Probes	68
Applications in Cells	71
Applications in Animals	76
Applications in Patients	80
6. Morpholinos and PNAs Compared	89
<i>James E. Summerton</i>	
Classification of Antisense Structural Types	90
Preparation of Morpholinos and PNAs	91
Properties of Morpholinos and PNAs	93
Applications	106
7. Chemistry of Locked Nucleic Acids (LNA): Design, Synthesis and Bio-Physical Properties	114
<i>Jesper Wengel, Michael Petersen, Miriam Frieden and Troels Koch</i>	
Synthesis of LNA Monomers	114
Solid Phase Synthesis of LNA Oligonucleotides	115
Hybridization Characteristics of LNA Oligonucleotides	118
Hybridization Kinetics of LNA Oligonucleotides	119
Structure of LNA Oligonucleotides	122
DNA and RNA Structure	122
LNA Structure	123
LNA:RNA Duplexes	123
LNA:DNA Duplexes	125
LNA:LNA Duplexes	126
α -L-LNA:RNA Duplexes	126
α -L-LNA:DNA Duplexes	126
Implications for RNase H Activity of LNA:RNA and α -L-LNA:RNA Duplexes	127
Stability of LNA and α -L-LNA Modified Nucleic Acids	127
LNA Triplexes	128
8. Recent Applications of RNA Interference (RNAi) in Mammalian Systems	133
<i>Lisa Scherer and John J. Rossi</i>	
siRNA Design	133
Recent Applications of RNAi	137
Functional Genomics	142
RNAi versus Ribozymes	143

Part II

Clinical Applications

9. **Peptide Nucleic Acids as Epigenetic Inhibitors of HIV-1** 151
Shizuko Sei
HIV-1 Life Cycle and Potential Molecular Targets 152
Genetic Strategies to Inhibit HIV-1 Replication 153
Peptide Nucleic Acids as Epigenetic HIV-1 Inhibitors 154
Potential Use of PNA Against Other Infectious Pathogens 161
Bio-Delivery of PNA 161
Future Perspectives 163
10. **Therapeutic Uses of Peptide Nucleic Acids (PNA) in Oncology** 171
Nadia Zaffaroni, Raffaella Villa and Marco Folini
Potential of PNAs as Tools for Anticancer
Therapeutic Interventions 172
Perspectives 178
11. **PNAs as Novel Cancer Therapeutics** 181
Luca Mologni and Carlo Gambacorti-Passerini
Biochemistry of Peptide Nucleic Acids 182
PNA as a Biomolecular Tool 183
Antisense and Anti-Gene Properties of PNA 184
Future Directions 189
12. **Medicinal Chemistry of Plasmid DNA with Peptide Nucleic Acids:**
A New Strategy for Gene Therapy 195
Olivier Zelfhati, Jiin Felgner, Yan Wang, Xiaowu Liang,
Xiaodong Wang and Philip Felgner
Principle of PNA Dependent Gene Chemistry Technology 197
Labeling of Plasmid DNA to Study Gene Delivery Mechanism 198
Transition 199
Overcoming the Barriers to Improve Gene Delivery
and Expression 200
PNA-Conjugates for Targeting DNA to Cell Surface Receptors 201
PNA-Peptide Conjugates to Overcome Cell Membrane Barriers 202
Other Potential Applications of PNA Conjugate
for Gene Delivery 206

13. Locked Nucleic Acids (LNA) and Medical Applications	212
<i>Henrik Ørum, Andreas Wolter and Lars Kongsbak</i>	
Biochemistry of LNA	212
LNA in Diagnostics and Genomics Applications	215
LNA in Therapeutic Applications	218
Future Perspectives on LNA	221
14. Peptide Nucleic Acids as Agents to Modify Target Gene Expression and Function	223
<i>Gan Wang and Peter M. Glazer</i>	
PNA Binding Affinity	224
PNA Binding Specificity	224
Detection of PNA Binding-Induced Transcription in HeLa Nuclear Extract in Vitro Transcription System	224
Determination of the Initiation Sites of PNA Binding-Induced Transcription	226
PNA Binding-Generated D-Loops Lead to GFP Gene Expression in Mammalian Cells	228
PNA-Induced Endogenous γ -Globin Gene Expression in Human Cells	228
The Correlation between PNA Binding-Generated D-Loops and the Natural Promoter of the Gene in Target Gene Transcription	229
The PNA Length Requirement for Inducing Transcription from the PNA Binding Sites	231
Transcription Components Involved in PNA Binding-Induced Transcription	232
The Limitation of PNA Binding-Induced Target Gene Expression	233
PNAs for Targeted Genome Modification	234
15. Peptide Nucleic Acids: Cellular Delivery and Recognition of DNA and RNA Targets	236
<i>David R. Corey</i>	
Hybridization by PNA: Affinity Isn't Everything	236
Strand Invasion by PNAs	238
Intracellular Delivery of PNAs	239
Applications for PNAs Delivered within Cells	240

16. The Use of PNAs and Their Derivatives in Mitochondrial Gene Therapy	243
<i>Paul M. Smith, Günther F. Ross, Theresa M. Wardell, Robert W. Taylor, Douglass M. Turnbull and Robert N. Lightowlers</i>	
The Antigenomic Hypothesis	244
PNA as the Choice of Antigenomic Agent	244
Cellular Uptake and the Problem of Mitochondrial Import	246
PNAs as Antigenomic Molecules – Do They Work?	247
Trouble-Shooting the Antigenomic Approach to mtDNA Disease	248
17. Gene Silencing through RNA Interference: Potential for Therapeutics and Functional Genomics	252
<i>David O. Azorsa, Spyro Mousset and Natasha J. Caplen</i>	
RNAi: An Historical Perspective	252
RNAi: Summary of Mechanism	253
Physiological Role of RNAi and Related Post-Transcriptional Gene Silencing Mechanisms	253
RNAi in Mammalian Cells	255
The Delivery of Triggers of RNAi	256
RNAi as a Functional Genomics Tool	257
RNAi as a Therapeutic Strategy	258
18. Transcriptional Activation of Human CREB Gene Promoter Using Bis-PNA (Peptide Nucleic Acid)	265
<i>Christopher G. Janson, Matthew J. During, Yelena Shifman and Paola Leone</i>	
Materials and Methods	266
Results	267
Future Directions for Trans-Activation in the Brain	268
Index	271

EDITORS

Christopher G. Janson

Departments of Neurosurgery, Neurology and Molecular Genetics
Cell and Gene Therapy Center
UMDNJ-Robert Wood Johnson Medical School
Camden, New Jersey, U.S.A.
Email: jansoncg@umdnj.edu

Chapter 18

Matthew J. During

Department of Molecular Medicine and Pathology
University of Auckland
Auckland, New Zealand
Email: m.during@auckland.ac.nz

Chapter 18

CONTRIBUTORS

David O. Azorsa
Translational Genomics Research
Institute (TGen)
Gaithersburg, Maryland, U.S.A.
Chapter 17

Lionel Bastide
Institute de Génétique Moléculaire
de Montpellier
Centre National de la Recherche
Scientifique
Universite Montpellier 2
UMR 5124, IGMM
Montpellier, France
Chapter 2

Ruben J. Boado
Department of Medicine
UCLA
Los Angeles, California, U.S.A.
Email: rboado@mednet.ucla.edu
Chapter 4

Natasha J. Caplen
Medical Genetics Branch
National Human Genome Research
Institute
National Institutes of Health
Bethesda, Maryland, U.S.A.
Email: ncaplen@nhgri.nih.gov
Chapter 17

David R. Corey
Departments of Pharmacology
and Biochemistry
University of Texas Southwestern
Medical Center
Dallas, Texas, U.S.A.
Email: david.corey@utsouthwestern.edu
Chapter 15

Jiin Felgner
Gene Therapy Systems Inc.
San Diego, California, U.S.A.
Chapter 12

Philip Felgner
University of California, Irvine
Center for Virus Research
Irvine, California, U.S.A.
Email: pfelgner@uci.edu
Chapter 12

Marco Folini
Dipartimento di Oncologia Sperimentale
Istituto Nazionale per lo Studio
e la Cura dei Tumori
Milan, Italy
Chapter 10

Miriam Frieden
Santaris Pharma A/S
Hørsholm, Denmark
Email: mfr@santaris.com
Chapter 7

Carlo Gambacorti-Passerini
Oncogenic Fusion Proteins Unit
Department of Experimental Oncology
National Cancer Institute
Milan, Italy
Chapter 11

Peter M. Glazer
Departments of Therapeutic Radiology
and Genetics
Yale University School of Medicine
New Haven, Connecticut, U.S.A.
Email: peter.glazer@yale.edu
Chapter 14

Leaf Huang
Center for Pharmacogenetics
Department of Pharmaceutical Sciences
School of Pharmacy
University of Pittsburgh
Pittsburgh, Pennsylvania, U.S.A.
Email: huangl@msx.upmc.edu
Chapter 3

Troels Koch
Santaris Pharma A/S
Hørsholm, Denmark
Email: tk@santaris.com
Chapter 7

Lars Kongsbak
Exiqon A/S
Vedbæk, Denmark
Email: kongsbak@exiqon.com
Chapter 13

Bernard Lebleu
Institute de Génétique Moléculaire
de Montpellier
Centre National de la Recherche
Scientifique
Universite Montpellier 2
UMR 5124, IGMM
Montpellier, France
Email: lebleu@jones.igm.cnrs-mop.fr
Chapter 2

Paola Leone
Cell and Gene Therapy Center
UMDNJ
Robert Wood Johnson Medical School
Camden, New Jersey, U.S.A.
Chapter 18

Kenneth W. Liang
Center for Pharmacogenetics
Department of Pharmaceutical Sciences
School of Pharmacy
University of Pittsburgh
Pittsburgh, Pennsylvania, U.S.A.
Chapter 3

Xiaowu Liang
Gene Therapy Systems Inc.
San Diego, California, U.S.A.
Chapter 12

Robert N. Lightowers
Department of Neurology
University of Newcastle upon Tyne
Medical School
Framlington Place
Newcastle upon Tyne, U.K.
Email: r.n.lightowers@ncl.ac.uk
Chapter 16

Feng Liu
Center for Pharmacogenetics
Department of Pharmaceutical Sciences
School of Pharmacy
University of Pittsburgh
Pittsburgh, Pennsylvania, U.S.A.
Chapter 3

Luca Mogni
Department of Clinical Medicine
University of Milano-Bicocca
Monza, Italy
and
Department of Experimental Oncology
National Cancer Institute
Milan, Italy
Email: luca.mogni@unimib.it
Chapter 11

Spyro Mousses
Translational Genomics Research
Institute (TGen)
Gaithersburg, Maryland, U.S.A.
Chapter 17

Peter E. Nielsen
Center for Biomolecular Recognition
Department of Medical Biochemistry
and Genetics
The Panum Institute
Copenhagen, Denmark
Email: pen@imbg.ku.dk
Chapter 1

Henrik Ørum
Santaris Pharma A/S
Hørsholm, Denmark
Email: hoe@santaris.com
Chapter 13

William M. Pardridge
Department of Medicine
UCLA
Los Angeles, California, U.S.A.
Email: wpardridge@mednet.ucla.edu
Chapter 4

Michael Petersen
Nucleic Acid Center
Department of Chemistry
University of Southern Denmark
Odense, Denmark
Email: mip@chem.sdu.dk
Chapter 7

Ian Robbins
Institute de Génétique Moléculaire
de Montpellier
Centre National de la Recherche
Scientifique
Montpellier, France
Email: ian.robbins@igmm.cnrs.fr
Chapter 2

Günther F. Ross
Mitochondrial Research Group
School of Neurology, Neurobiology
and Psychiatry
University of Newcastle upon Tyne
Framlington Place
Newcastle upon Tyne, U.K.
Chapter 16

John J. Rossi
Division of Molecular Biology
Beckman Research Institute
of the City of Hope
Duarte, California, U.S.A.
Email: jrossi@coh.org
Chapter 8

Edward R. Sauter
Department of Surgery
Ellis Fischel Cancer Center
University of Missouri
Columbia, Missouri, U.S.A.
Chapter 5

Lisa Scherer
Division of Molecular Biology
Beckman Research Institute
of the City of Hope
Duarte, California, U.S.A.
Email: lscherer@coh.org
Chapter 8

Shizuko Sei
Laboratory of Antiviral Drug
Mechanisms
Screening Technologies Branch
Developmental Therapeutics Program
SAIC-Frederick, NCI-Frederick
Frederick, Maryland, U.S.A.
Email: SEI@dtpx2.ncifcrf.gov
Chapter 9

Yelena Shifman
Cell and Gene Therapy Center
UMDNJ
Robert Wood Johnson Medical School
Camden, New Jersey, U.S.A.
Chapter 18

Paul M. Smith
Mitochondrial Research Group
School of Neurology, Neurobiology
and Psychiatry
University of Newcastle upon Tyne
Framlington Place
Newcastle upon Tyne, U.K.
Chapter 16

James E. Summerton
Gene Tools, LLC
Philomath, Oregon, U.S.A.
Email: jsummerton@gene-tools.com
Chapter 6

Robert W. Taylor
Mitochondrial Research Group
School of Neurology, Neurobiology
and Psychiatry
University of Newcastle upon Tyne
Framlington Place
Newcastle upon Tyne, U.K.
Chapter 16

Mathew L. Thakur
Department of Radiology
Kimmel Cancer Center
Jefferson Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania, U.S.A.
Chapter 5

Douglass M. Turnbull
Mitochondrial Research Group
School of Neurology, Neurobiology
and Psychiatry
University of Newcastle upon Tyne
Framlington Place
Newcastle upon Tyne, U.K.
Chapter 16

Raffaella Villa
Dipartimento di Oncologia Sperimentale
Istituto Nazionale per lo Studio
e la Cura dei Tumori
Milan, Italy
Chapter 10

Gan Wang
Department of Cell Biology
and Neuroscience
University of South Alabama
Mobile, Alabama
Chapter 14

Xiaodong Wang
Gene Therapy Systems Inc.
San Diego, California, U.S.A.
Chapter 12

Yan Wang
Gene Therapy Systems Inc.
San Diego, California, U.S.A.
Chapter 12

Theresa M. Wardell
Mitochondrial Research Group
School of Neurology, Neurobiology
and Psychiatry
University of Newcastle upon Tyne
Framlington Place
Newcastle upon Tyne, U.K.
Chapter 16

Jesper Wengel
Nucleic Acid Center
Department of Chemistry
University of Southern Denmark
Odense, Denmark
Email: jwe@chem.sdu.dk
Chapter 7

Eric Wickstrom
Department of Biochemistry
and Molecular Biology
Department of Microbiology
and Immunology
Kimmel Cancer Center
Cardeza Foundation for Hematologic
Research
Jefferson Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania, U.S.A.
Email: eric@tesla.jci.tju.edu
Chapter 5

Andreas Wolter
Proligo GmbH
Hamburg, Germany
Email: awolter@proligo.com
Chapter 13

Nadia Zaffaroni
Dipartimento di Oncologia Sperimentale
Istituto Nazionale per lo Studio
e la Cura dei Tumori
Milan, Italy
Email: zaffaroni@istitutotumori.mi.it
Chapter 10

Olivier Zelphati
University of California, Irvine
Center for Virus Research
Irvine, California, U.S.A.
Email: zelphati@aol.com
Chapter 12

PREFACE

When this book project was first contemplated, some of the molecules and applications discussed in this volume (such as mammalian siRNA) did not yet exist, which speaks to the relative progress in the antisense field and the likelihood that further chemical modifications of existing classes of molecules will lead to even more enhanced and greater use of “gene tools” in the future. The original intention of the publisher was to devote an entire book to Peptide Nucleic Acid (PNA), which was an incipient but fast-growing field. Given the diversity of emerging antisense products, we felt that it would be more profitable to compare and contrast PNA with other available oligonucleotide homologues and to consider areas in which these biomolecules could be profitably applied to clinical and diagnostic applications. Because other books and research articles in the primary literature already provided specific protocols for use of PNA and related compounds, we preferred to take a broader review of the existing literature by some of the same innovators who developed the molecules and associated techniques.

There are currently a wide variety of research tools to choose from in the design of experiments utilizing gene knockdown and gene labeling, and the eight chapters in Part I address comparative strengths and weaknesses of various nucleoside homologues: standard modified DNA oligonucleotides, peptide nucleic acid (PNA), locked nucleic acid (LNA), morpholinos, and small interfering RNA (siRNA). In terms of unique properties, PNA is especially useful in situations where DNA binding affinity and resistance to nucleases is important such as gene-based diagnostics, or where another ligand is to be bound to DNA for site-specific mutagenesis, gene-specific drug delivery, or other demanding applications. Other currently popular molecules such as siRNA, LNA, and morpholinos are all efficient and versatile methods of knockdown for *in vivo* use, but each has distinct advantages and limitations. Some molecules are limited to acting on the RNA level (e.g., siRNA), while others work on the DNA or RNA level (e.g., LNA, PNA, morpholinos). After an overview of the basic characteristics of each “gene tool,” the ten chapters in Part II address specific translational or clinical applications for PNA and related antisense biomolecules, such as anti-tumor or anti-AIDS therapies, gene activation, and gene repair.

The editors have aimed to present a balanced view of the methods available for gene targeting and modification, which will have broad appeal for either the research scientist or gene therapist. In the process we have omitted some techniques which originally appeared to have promise but which have subsequently been cast into serious doubt in terms of their specificity and effectiveness, such as DNA-RNA chimeraplasty. The molecules

discussed in this volume are widely considered to be beyond reproach in terms of their potential utility in the research setting, despite the fact that they are still proving themselves in the laboratory and have yet to enter the clinic. Because the same “gene tools” may not be equally effective in research and in the clinic—indeed, it is quite possible that the opposite will be true—we have aimed to strike a balance between the bench and the bedside.

*Christopher G. Janson
Matthew J. During*